[fr] Le lymphome B diffus à grandes cellules (LBDGC) regroupe un nombre de plus en plus grand d'entités dont les carat:téristiques anatomocliniques diffèrent. La thérapeutique actuelle recourt à une immunochimiothérapie couplant le rituximab à la polychimiothérapie dont les composants, leurs posologies et leurs fréquences d'administration dépendent de variables pronostiques préthérapeutiques mondialement reconnues. La tomographie à émission de positrons est réalisée lors des bilans initiaux et de ftn de traitement et de plus en plus lors de l'évaluation à mi-parcours de la chimiothérapie. En cas de rechute, la greffe de cellules souches du sang périphérique reste la seule chance de guérison. Cette revue synthétise l'état actuel de nos connaissances et souUgne les pistes suivies pour améliorer les résultats thérapeutiques actuels. [en] Diffuse Large B Cells Lymphoma (DLBCLI is the mast comman non-Hodgkin Iymphoma and comprises a large numberof different entities with different clinico-pathological characteristics. The role of positron emission tomography is essential dudog the Ini tial staging and post treatment assessment, and potentially at early or
mid-treatmentevaluation of response. First-line therapy comprises immuno-chemotherapy with rituximab and different cytotox ic agents that differforcomponents, dosages and frequency of administration taking worldwlderecognized pre-treatment prognostic variables into account. After relapse, peripheral blood
stem cells transplantation remains the only chance of cu re. This review attempts to summarize the current state of our knowledge by highlighting the leads pursued to further improve current therapeutic results.
** Swerdlow SH, Campo E, Harris NL, et al. WHO Classification of tumors of haematopoietic and lymphoid tissues. 2008.
Aukema SM, Siebert R, Schuuring E, et al. Doublehit B-cell lymphomas. Blood 2011;117:2319-31.
Jaffe ES, Pittaluga S. Aggressive B-cell lymphomas : A review of new and old entities in the WHO classification. Hematology Am Soc Hematol Educ Program 2011;2011:506-14.
Alizadeh AA, Eisen MB, Davis RE, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 2000;403:503-11. (Pubitemid 30082188)
* Jerusalem G, Beguin Y. The place of positron emission tomography imaging in the management of patients with malignant lymphoma. Haematologica 2006;91:442-4.
Jerusalem G, Hustinx R, Beguin Y, et al. Evaluation of therapy for lymphoma. Semin Nucl Med 2005;35:186-96. (Pubitemid 41138137)
Hutchings M, Specht L. PET/CT in the management of haematological malignancies. Eur J Haematol 2008; 80:369-80. (Pubitemid 351503112)
Zucca E, Roggero E, Bertoni F, et al. Primary extranodal non-Hodgkin's lymphomas. Part 2 : Head and neck, central nervous system and other less common sites. Ann Oncol 1999;10:1023-33. (Pubitemid 29482456)
** Zelenetz AD, Abramson JS, Advani RH, et al. NCCN Clinical Practice Guidelines in Oncology : Non-Hodgkin's lymphomas. J Natl Compr Canc Netw 2010; 8:288-334.
A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med 1993;329:987-94.
Ziepert M, Hasenclever D, Kuhnt E, et al. Standard international prognostic index remains a valid predictor of outcome for patients with aggressive CD20+ B-cell lymphoma in the rituximab era. J Clin Oncol 2010; 28:2373-80.
Sehn LH, Berry B, Chhanabhai M, et al. The Revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood 2007;109:1857-61. (Pubitemid 46348180)
* Coiffier B, Thieblemont C, Van Den Neste E, et al. Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients : A study by the Groupe d'études des lymphomes de l'adulte. Blood 2010;116:2040-5.
Copie-Bergman C, Gaulard P, Leroy K, et al. Immuno-fluorescence in situ hybridization index predicts survival in patients with diffuse large B-cell lymphoma treated with R-CHOP : A GELA study. J Clin Oncol 2009;27:5573-9.
Seki R, Ohshima K, Fujisaki T, et al. Prognostic impact of immunohistochemical biomarkers in diffuse large B-cell lymphoma in the rituximab era. Cancer Sci 2009;100:1842-7.
Choi WW, Weisenburger DD, Greiner TC, et al. A new immunostain algorithm classifies diffuse large Bcell lymphoma into molecular subtypes with high accuracy. Clin Cancer Res 2009;15:5494-502.
Gutierrez-Garcia G, Cardesa-Salzmann T, Climent F, et al. Gene-expression profiling and not immunophenotypic algorithms predicts prognosis in patients with diffuse large B-cell lymphoma treated with immunochemotherapy. Blood 2011;117:4836-43.
Hans CP, Weisenburger DD, Greiner TC, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 2004;103:275-82. (Pubitemid 38029949)
Cuccuini W, Briere J, Mounier N, et al. MYC+ diffuse large B-cell lymphoma is not salvaged by classical R-ICE or R-DHAP followed by BEAM plus autologous stem cell transplantation. Blood 2012;119:4619-24.
Bonnet C, Fillet G, Mounier N, et al. CHOP alone compared with CHOP plus radiotherapy for localized aggressive lymphoma in elderly patients : A study by the Groupe d'étude des lymphomes de l'adulte. J Clin Oncol 2007;25:787-92. (Pubitemid 350002878)
Pfreundschuh M, Trumper L, Osterborg A, et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma : A randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol 2006;7:379-91.
Phan J, Mazloom A, Medeiros LJ, et al. Benefit of consolidative radiation therapy in patients with diffuse large B-cell lymphoma treated with R-CHOP chemotherapy. J Clin Oncol 2010;28:4170-6.
Yahalom J. Radiation therapy after R-CHOP for diffuse large B-cell lymphoma : The gain remains. J Clin Oncol 2010;28:4105-7.
* Recher C, Coiffier B, Haioun C, et al. Intensified chemotherapy with ACVBP plus rituximab versus standard CHOP plus rituximab for the treatment of diffuse large B-cell lymphoma (LNH03-2B) : An open-label randomised phase 3 trial. Lancet 2011;378:1858-67.
Milpied N, Deconinck E, Gaillard F, et al. Initial treatment of aggressive lymphoma with high-dose chemotherapy and autologous stem-cell support. N Engl J Med 2004;350:1287-95. (Pubitemid 38375363)
Haioun C, Lepage E, Gisselbrecht C, et al. Benefit of autologous bone marrow transplantation over sequential chemotherapy in poor-risk aggressive non-Hodgkin's lymphoma : Updated results of the prospective study LNH87-2. Groupe d'étude des lymphomes de l'adulte. J Clin Oncol 1997;15:1131-7. (Pubitemid 27106299)
Casasnovas O, Meignan M, Berriolo A, et al. Interim 18fluorodeoxyglucose positron emission tomography SUVmax reduction is superior to visual analysis to predict early parient's outcome in diffuse large B-cell lymphoma. Blood (ASH annual meeting abstract) 2010; 116: abstract No 320.
Schmitz N, Nickelsen M, Ziepert M, et al. Aggressive chemotherapy (CHOEP-14) and rituximab or high-dose therapy (MegaCHOEP) and rituximab for young, high-risk patients with aggressive B-Cell lymphoma : Results of the MegaCHOEP trial of the German High- grade Non-Hodgkin Lymphoma Study Group (DSHNHL). Blood (ASH annual meeting abstract) 2009;114: abstract No 404.
Pfreundschuh M, Schubert J, Ziepert M, et al. Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas : A randomised controlled trial (RICOVER-60). Lancet Oncol 2008;9:105-16.
Cunningham D, Smith P, Mouncey P, et al. R-CHOP14 versus R-CHOP21 : Result of a randomized phase III trial for the treatment of patients with newly diagnosed diffuse large B-cell non Hodgkin lymphoma. J Clin Oncol (ASCO annual meeting abstract) 2011;29 (Suppl. 15): abstract No 8000.
Delarue R, Tilly H, Salles G, et al. R-CHOP14 compared to R-CHOP21 in elderly patients wih diffuse large B-cell lymphoma (DBCL) : Results of the second interim analysis of the LNH03-6B GELA study. Ann Oncol 2011;22(Suppl. 4).
Peyrade F, Jardin F, Thieblemont C, et al. Attenuated immunochemotherapy regimen (R-miniCHOP) in elderly patients older than 80 years with diffuse large B-cell lymphoma : A multicentre, single-arm, phase 2 trial. Lancet Oncol 2011;12:460-8.
Tilly H, Lepage E, Coiffier B, et al. Intensive conventional chemotherapy (ACVBP regimen) compared with standard CHOP for poor-prognosis aggressive non-Hodgkin lymphoma. Blood 2003;102:4284-9. (Pubitemid 37494085)
Boehme V, Schmitz N, Zeynalova S, et al. CNS events in elderly patients with aggressive lymphoma treated with modern chemotherapy (CHOP-14) with or without rituximab : An analysis of patients treated in the RICOVER-60 trial of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL). Blood 2009;113:3896-902.
Reyes F, Lepage E, Ganem G, et al. ACVBP versus CHOP plus radiotherapy for localized aggressive lymphoma. N Engl J Med 2005;352:1197-205. (Pubitemid 40397261)
Bonnet C, Fillet G, Mounier N. How can we determine the role of radiotherapy in the treatment of localized aggressive non-hodgkin's lymphoma ? J Clin Oncol 2007;25:3958-64.
Miller TP, Dahlberg S, Cassady JR, et al. Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate- and high-grade non-Hodgkin's lymphoma. N Engl J Med 1998;339:21-6. (Pubitemid 28304493)
Miller TP, Unger JM, Spier C, et al. Effect of adding rituximab to three cycles of CHOP plus invoved-field radiotherapy for limited-stage aggressive diffuse B-cell lymphoma (SWOG-0014). Blood (ASH annual meeting abstract) 2004 ;104 : abstract No 158.
Ghesquieres H, Ferlay C, Sebban C, et al. Longterm follow-up of an age-adapted C5R protocol followed by radiotherapy in 99 newly diagnosed primary CNS lymphomas : A prospective multicentric phase II study of the Groupe d'étude des lymphomes de l'adulte (GELA). Ann Oncol 2010;21:842-50.
Vitolo U, Chiappella A, Ferreri AJ, et al. First-line treatment for primary testicular diffuse large B-cell lymphoma with rituximab-CHOP, CNS prophylaxis, and contralateral testis irradiation : Final results of an international phase II trial. J Clin Oncol 2011;29:2766-72.
Rieger M, Osterborg A, Pettengell R, et al. Primary mediastinal B-cell lymphoma treated with CHOP-like chemotherapy with or without rituximab : Results of the Mabthera International Trial Group study. Ann Oncol 2011;22:664-70.
Haioun C, Itti E, Rahmouni A, et al. [18F]fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) in aggressive lymphoma : An early prognostic tool for predicting patient outcome. Blood 2005;106:1376-81. (Pubitemid 41129604)
Itti E, Lin C, Dupuis J, et al. Prognostic value of interim 18F-FDG PET in patients with diffuse large B-Cell lymphoma : SUV-based assessment at 4 cycles of chemotherapy. J Nucl Med 2009;50:527-33.
Juweid ME, Stroobants S, Hoekstra OS, et al. Use of positron emission tomography for response assessment of lymphoma : Consensus of the imaging subcommittee of international harmonization project in lymphoma. J Clin Oncol 2007;25:571-8. (Pubitemid 350002965)
Cheson BD, Pfistner B, Juweid ME, et al. Revised response criteria for malignant lymphoma. J Clin Oncol 2007;25:579-86. (Pubitemid 350002966)
** Tilly H, Dreyling M. Diffuse large B-cell non-Hodgkin's lymphoma : ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010;21 (Suppl. 5):v172-v174.
Gisselbrecht C, Glass B, Mounier N, et al. Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era. J Clin Oncol 2010;28:4184-90.
Philip T, Guglielmi C, Hagenbeek A, et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med 1995;333:1540-5.
Thieblemont C, Briere J, Mounier N, et al. The germinal center/activated B-cell subclassification has a prognostic impact for response to salvage therapy in relapsed/refractory diffuse large B-cell lymphoma : A bio-CORAL study. J Clin Oncol 2011;29:4079-87.
van Kampen RJ, Canals C, Schouten HC, et al. Allogeneic stem-cell transplantation as salvage therapy for patients with diffuse large B-cell non-Hodgkin's lymphoma relapsing after an autologous stem-cell transplantation : An analysis of the European Group for Blood and Marrow Transplantation Registry. J Clin Oncol 2011;29:1342-8.
El GT, Dupuis J, Belhadj K, et al. Rituximab, gemcitabine and oxaliplatin : An effective salvage regimen for patients with relapsed or refractory B-cell lymphoma not candidates for high-dose therapy. Ann Oncol 2007;18:1363-8. (Pubitemid 47305011)
Dupire S, Coiffier B. Targeted treatment and new agents in diffuse large B cell lymphoma. Int J Hematol 2010;92:12-24.
